PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECOND SUPPLEMENT TO PATENT SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date	
R2 Technology, Inc.	05/07/2008	

RECEIVING PARTY DATA

Name:	GOLDMAN SACHS CREDIT PARTNERS L.P., as collateral agent			
Street Address:	o/o Goldman, Sachs & Co.			
Internal Address:	30 Hudson Street, 36th Floor			
City:	Jersey City			
State/Country:	NEW JERSEY			
Postal Code:	07302			

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	7359538

CORRESPONDENCE DATA

Fax Number: (714)755-8290

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 714-540-1235

Email: ipdocket@lw.com, kristin.azcona@lw.com

Correspondent Name: LATHAM & WATKINS LLP

Address Line 1: 650 Town Center Drive, 20th Floor Address Line 4: Costa Mesa, CALIFORNIA 92626

ATTORNEY DOCKET NUMBER: 022411-0808

NAME OF SUBMITTER: Kristin J. Azcona

Total Attachments: 6

source=Hologic 2nd Patent supp#page1.tif source=Hologic 2nd Patent supp#page2.tif source=Hologic 2nd Patent supp#page3.tif

PATENT REEL: 021076 FRAME: 0704

500564260

OP \$40.00 7359

source=Hologic 2nd Patent supp#page4.tif source=Hologic 2nd Patent supp#page5.tif source=Hologic 2nd Patent supp#page6.tif

Patent Supplement

SECOND SUPPLEMENT TO PATENT SECURITY AGREEMENT

This Second Supplement to Patent Security Agreement (this "Supplement") is dated as of May 7, 2008, effective as of April 30, 2008, is made and entered into by and between Hologic, Inc., R2 Technology, Inc., Suros Surgical Systems, Inc., BioLucent LLC, Direct Radiography Corp., Cytyc Corporation and Cytyc Surgical Products Limited Partnership (collectively, the "Grantors"), and Goldman Sachs Credit Partners L.P., in its capacity as collateral agent for the Secured Parties (together with any successors and assigns thereto in such capacity, the "Collateral Agent").

WITNESSETH:

WHEREAS, Grantors are a party to a Pledge and Security Agreement dated as of October 22, 2007 (as amended, restated, amended and restated, supplemented and/or otherwise modified to date and from time to time, the "Pledge and Security Agreement") between each of the Grantors and the other grantors party thereto and the Collateral Agent;

WHEREAS, pursuant to the Pledge and Security Agreement, the Grantors executed and delivered to the Collateral Agent a Patent Security Agreement dated as of October 22, 2007 (as amended, restated, amended and restated, supplemented and/or otherwise modified to date and from time to time, the "Patent Security Agreement") by and between the Grantors and Collateral Agent; and

WHEREAS, this Supplement shall amend and supplement the Patent Security Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

- 1. <u>DEFINED TERMS</u> capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Pledge and Security Agreement and the Patent Security Agreement, as applicable.
- 2. <u>SCHEDULE I TO PATENT SECURITY AGREEMENT.</u> Schedule I of the Patent Security Agreement is hereby revised by adding thereto the Patent Collateral listed on Section 1 of Exhibit A hereto and deleting therefrom the Patent Collateral listed on Section 2 of Exhibit A hereto.

3. <u>MISCELLANEOUS.</u>

a. <u>Counterparts</u>. This Supplement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Supplement. Delivery of an executed counterpart of this Supplement by facsimile shall be equally as effective as delivery of an original executed

NY\1398585.7

counterpart of this Supplement. Any party delivering an executed counterpart of this Supplement by facsimile also shall deliver an original executed counterpart of this Supplement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Supplement. This Supplement shall be deemed to be a Credit Document.

b. <u>Governing Law</u>. This Supplement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any conflict or choice of laws rules or provisions (other than Section 5-1401 and Section 5-1402 of the New York General Obligation Laws).

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

NY\1398585.7

IN WITNESS WHEREOF, each Grantor has caused this Supplement to be executed and delivered by its duly authorized officer as of the date first set forth above.

HOLOGIC, INC., as Grantor

Title: Chief Accounting Officer

R2 TECHNOLOGY, INC., as Grantor

Name: Robert H. LaVallee

Title: Vice President and Assistant Treasurer

SUROS SURGICAL SYSTEMS, INC., as

Grantor

Name: Robert H. LaVallee

Title: Vice President and Assistant Treasurer

BIOLUCENT, LLC, as Grantor

By: Hologic, Inc., its sole member and sole

manager

By: Relent H. Loroller Name: Robert H. LaVallee

Title: Chief Accounting Officer

DIRECT RADIOGRAPHY CORP., as Grantor

Name: Robert H. LaVallee

Title: Vice President and Assistant Treasurer

CYTYC CORPORATION, as Grantor

Name: Robert H. LaVallee

Title: Senior Vice President and Assistant Treasurer

CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP, as Grantor

By: Cytyc Corporation, its general partner

Name: Robert H. LaVallee

Title: Senior Vice President and Assistant Treasurer

Accepted and Agreed:

GOLDMAN SACHS CREDIT PARTNERS L.P.,

as Collateral Agent

Name Title:

James V. Balcom Authorized Signatory

[Hologie Second Patent Supplement]

EXHIBIT A

1. PATENT AND PATENT APPLICATIONS TO BE ADDED TO SCHEDULE I TO PATENT SECURITY AGREEMENT

Granted

Title	App. No.	Pat. No.	Status	Country	Filing Date	Issue Date	Owner
Detection and Analysis					9		Ottiler
of Lesions in Contact		ļ					
with a Structural		Ì				ľ	
Boundary	10/261.184	7359538	Granted	ŲŠ	09-30-02	04-15-08	R2

Pending

			1		T
Title	App. No.	Status	Country	Filing Date	Owner
System & Method for Minimally Invasive				, timi, Date	OWILL
Disease Therapy	12/061,195	Pending	US	04-02-08	Suros
System & Method for Minimally Invasive				0.02.00	Duroa
Disease Therapy	12/061,344	Pending	US	04-02-08	Suros

PATENT AND PATENT APPLICATIONS TO BE DELETED FROM SCHEDULE I TO 2. PATENT SECURITY AGREEMENT

[INTENTIONALLY OMMITTED]

RECORDED: 06/11/2008